It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The morbidity of aneurysmal subarachnoid hemorrhage (aSAH) remains high, particularly because of secondary cerebral lesions that significantly aggravate the primary lesions. The main type of secondary lesions is delayed cerebral ischemia (DCI), in which platelets (PLT) appear to play a key role. Mean platelet volume (MPV) is an indirect marker of platelet activation. We aimed to determine the individual trajectories of MPV over time in patients with and without DCI during the course of aSAH. This is a single-center, retrospective, longitudinal analysis of individual trajectories of MPV over time, in a cohort of aSAH patients included in the Prospective, Observational Registry of Patient with Subarachnoid Hemorrhage in Neurocritical Care Unit (ProReSHA). A mixed-effects linear regression model was used to compare the trajectories of MPV and MPV/PLT ratio between patients who developed a DCI and those who did not. A total of 3634 MPV values were collected in 587 patients. The analysis of MPV as a function of DCI occurrence showed a significant difference in the trajectory over time between patients with DCI and those without, with an estimate of 0.02 (95%CI 0.01, 0.04, p = 0.009). The analysis of the MPV/PLT ratio as a function of DCI occurrence and other covariates showed a significant difference in the trajectory over time only for patients with a modified Fisher score less than 3, with an estimate of -0.59 (95%CI: -0.94, -0.23, p = 0.001). The individual trajectories of MPV over time differ between patients with DCI and those without. However, MPV values vary greatly over time and between patients. Thus it does not appear as a reliable biomarker for stratifying patients based on their specific risk of developing DCI. ClinicalTrials.gov identifier: (NCT02890004), registered in August 2016.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon (Lyon University Hospital), Département d’Anesthésie et Réanimation, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
2 Hospices Civils de Lyon, Service de Biostatistiques, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
3 Médipôle Lyon-Villeurbanne, Service de Réanimation Polyvalente, Ramsay Santé, France (GRID:grid.413852.9)
4 Hospices Civils de Lyon, Laboratoire d’Hématologie-Hémostase, Centre de Biologie et Pathologie Est, Bron, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825)
5 Hopital Neurologique Pierre Wertheimer, Hospices Civils de Lyon (Lyon University Hospital), Département d’Anesthésie et Réanimation, Lyon, France (GRID:grid.413852.9) (ISNI:0000 0001 2163 3825); INSERM U1028/CNRS, UMR 5292, University of Lyon, Lyon Neurosciences Research Center, Lyon, France (GRID:grid.461862.f) (ISNI:0000 0004 0614 7222)